(Information sent by the signatory company)
Dragonfly also announced this week that its first TriNKET, DF1001 targeting HER2, has entered Phase 2. In its Phase 1 study, DF1001 was well tolerated and showed an encouraging clinical response, with reductions in tumor burden across several tumor types. , even in low HER2 and heavily previously treated patients
WALTHAM, Mass., Dec. 8, 2022 /PRNewswire/ -- Dragonfly Therapeutics, Inc. ("Dragonfly" or the company), a clinical-stage biotechnology company developing novel immunotherapies, today announced the first patient dosing in a TriNKET Phase 1/2 study targeting company's proprietary EGFR.
DF9001 is the sixth drug developed by Dragonfly to undergo clinical trials. The company's first TriNKET, DF1001, entered Phase 2 trials this month after being well-tolerated in Phase 1 with encouraging clinical responses, including demonstration of reductions in tumor burden in various tumor types, including in HER2-low patients and heavily pre-treated patients.
"Given our positive experience over the past two years with Dragonfly's HER2-targeted TriNKET DF1001, we are excited to begin offering patients an even broader set of solid tumor cancers from this new EGFR-targeted therapy," Howard explained. P. Safran, MD, chief of Hematology/Oncology at the Lifespan Cancer Institute and medical director of the Oncology Group at Brown University. "We see an opportunity for Dragonfly's next generation of NK cell-involving immune oncology therapies to directly attack solid tumor cancers, recruit T cells in cold tumor environments, and offer a broader therapeutic index, helping patients currently they have very few other therapeutic options."
"The initiation of clinical trials with the sixth drug candidate developed by Dragonfly demonstrates how comprehensively we and our pharmaceutical partners are delivering new treatment options that are critically needed for cancer patients," said Jean-Marie Cuillerot, Dragonfly's chief medical officer. .
Dragonfly Therapeutics' Phase 1/2 DF9001 clinical trial is a first-in-human, multi-part, open-label, non-randomized, multiple-ascending-dose clinical trial to investigate the safety, tolerability, pharmacokinetics, biologic and clinical activity of DF9001 alone. and in combination with a PD-1 checkpoint inhibitor in patients with locally advanced or metastatic solid tumors, followed by expansion in selected indications, including head and neck squamous cell carcinoma (HNSCC), colorectal cancer ( CRC) and non-small cell lung cancer (NSCLC).
Additional information about the trial, including eligibility criteria, can be found at: https://clinicaltrials.gov (ClinicalTrials.gov Identifier: NCT05597839).
About Dragonfly
Dragonfly Therapeutics is a clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of therapies that use its novel bispecific antibody technology to harness the body's innate immune system and deliver innovative treatments to patients. Dragonfly has a large pipeline of wholly owned preclinical candidates discovered using its proprietary platform that are progressing into the clinic, as well as productive collaborations with Merck, AbbVie, Gilead, and Bristol Myers Squibb across a wide range of disease areas.
For more information, visit: www.dragonflytx.com https://www.linkedin.com/company/dragonfly-therapeutics-inc./ https://twitter.com/dragonflytx
DRAGONFLY MEDIA CONTACT: Anne E. Deconinck | anne@dragonflytx.com
Logo - https://mma.prnewswire.com/media/390962/...
View original content: https://www.prnewswire.com/news-releases/dragonfly-therapeutics-anuncia-el-primer-paciente-dosificado-en-el-estudio-de-fase-1-trinket-dirigido-a-egfr-301698496.html
